Skip to main content
Figure 3 | Alzheimer's Research & Therapy

Figure 3

From: Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

Figure 3

Proportion of patients showing marked clinical worsening (ITT set, LOCF analysis). aModerate to severe AD (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day). bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). *P < 0.01 versus placebo added to donepezil; **P < 0.001 versus placebo added to donepezil. AD, Alzheimer's disease; ITT, intention-to-treat; LOCF, last observation carried forward.

Back to article page
\